Data study · analyzed August 2026
State of the Peptide Community 2026
We read and classified 1,734 real discussions from the peptide communities on Reddit and X — not to count hashtags, but to answer what people actually experience: what works, what goes wrong, how they really dose these compounds, and which ones the community is quietly disappointed by.
Medically reviewed by Marko Maal, MSc Pharmacy · Source: the live community-signal feed
The takeaways
Key findings
- 1Dosing anxiety — not results — drives the conversation: 28% of all discussion is about how to dose, titrate, and cycle.
- 2Read the experiences and they're majority mixed-to-negative: only 28% describe a clear success, 41% are mixed, 33% didn't work.
- 3The newest drug is winning the sentiment war: retatrutide (+0.34) beats the two most-used GLP-1s, semaglutide (+0.16) and tirzepatide (+0.20).
- 4The people deepest into GLP-1 use are the least satisfied — a plateau-and-tolerance problem hiding under the enthusiasm.
- 5The community surfaces specific safety signals ahead of the literature — MOTS-c histamine reactions, Selank tolerance after 2–3 doses, GHK-Cu sleep disruption.
What the experiences actually say
Most first-hand accounts are mixed, not glowing
Of the experience posts we hand-curated with a verdict, only about one in four described an unambiguous success. Read what people write and the peptide conversation is far more sober than the marketing around it.
Post intent
The biggest anxiety is dosing, not results
Every post classified by intent. Dosing and titration is the number-one practical concern, nearly matching experience-sharing — a population that's already decided to use peptides and is anxious about doing it right.
Sentiment
The newest drug is winning; the incumbents are losing
Ranked by average sentiment. The counterintuitive result: the two most-used, most-discussed GLP-1s score near the bottom, while newer retatrutide leads. The people furthest into the journey are the least satisfied.
Amber = FDA-approved GLP-1. Right column: average sentiment · mentions.
Compound by compound
What people actually struggle with
The part a mention-count can't tell you: the real problem each major peptide is generating, and how people are using it — distilled from the discussions themselves.
Tirzepatide
172 mentions · +0.20The plateau and fading appetite suppression — users stall and read it as the drug “wearing off,” rather than physiology or unfinished titration.
Reported use: 2.5 → 5 → 7.5 → 12.5 → 15 mg weekly, subcutaneous.
Retatrutide
163 mentions · +0.34Constipation and very strong appetite suppression — but the enthusiasm leader. Users report deliberate cycling, ~8–9 months on with breaks.
Reported use: 0.5–4 mg/week, subcutaneous.
MOTS-c
113 mentions · +0.34Histamine reactions within five minutes of injection — welts under the skin, itching at the site. A specific safety signal mainstream sources miss.
Reported use: 2–5 mg, subcutaneous.
GHK-Cu
95 mentions · +0.24Forehead congestion and small bumps, injection-site burning on longer courses, and sleep disruption when restarting.
Reported use: 1–2.5 mg daily, cycled 4–12 weeks.
BPC-157
120 mentions · +0.21Overwhelmingly injection-site issues — bruising, lumps, soreness — not systemic problems. Its FDA status drives a large share of the talk.
Reported use: 200–400 mcg/day, 4–9 week courses; usually stacked with TB-500.
Semax
76 mentions · +0.29Overstimulation — anxiety, headache — often compounded by stacking with Adderall.
Reported use: 300–700 mcg intranasal, 2–4 week on/off cycles.
Selank
42 mentions · +0.25Rapid tolerance: users report the effect fading after just 2–3 doses.
Reported use: 200–600 mcg intranasal, 2–4 week cycles.
KPV
74 mentions · +0.15The sentiment cellar-dweller: increased appetite, an initial eczema flare, and a “head buzzing” sensation against an anti-inflammatory promise.
Reported use: 250–500 mcg.
Interpretation
What this means
The peptide audience is past the awareness stage and deep into the practical stage — dosing, cycling, side-effect management and stacking are the live questions, and they are poorly served by hype-driven content that leads with before-and-after photos.
The lived experience is far more mixed than the marketing, and the people deepest into GLP-1 use are the least satisfied — a plateau-and-tolerance problem hiding under the enthusiasm.
And the community is surfacing real, specific safety signals — MOTS-c histamine reactions, Selank tolerance, GHK-Cu sleep effects — ahead of, and sometimes instead of, the formal literature. None of this is medical advice, and community signal is not clinical evidence — but as a map of what real people are doing with peptides in 2026, it is more honest than any mention-count.
For journalists & writers
This data is free to cite with attribution and a link to mypeptidestory.com. Our reviewing pharmacist, Marko Maal (MSc), is available for quotes and context. For the underlying methodology or a specific breakdown, reach us via the editorial page.
Suggested citation: “State of the Peptide Community 2026,” My Peptide Story. mypeptidestory.com/signal/state-of-the-peptide-community-2026
Methodology
1,734 on-topic posts were collected from public Reddit and X peptide communities via public APIs, deduplicated, and each machine-classified by intent (experience, dosing, question, side-effect, research, vendor, regulatory) and by compound, then sentiment-scored (approx. −1 to +1). Experience highlights and the worked/mixed/ didn't verdicts were hand-curated with verbatim quotes validated against the source post. Per-compound “reported use” and problems are distilled from those discussions. This is community signal, not clinical evidence — it measures what people discuss and report, not what is proven to work. Explore the live feed at /signal.